Payment overview · 2025
General Payments
$188.91
16 reported records · 2 companies
Healthcare provider profile · identity verified
Marshalvia Bryant, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · GREENVILLE, MS · NPI 1083366975
Verified facts
What the public records show
CMS Open Payments records show Marshalvia Bryant, NP received $188.91 in general payments during 2025 across 16 reported records.
ViiV Healthcare Company accounted for 75.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Dovato.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $142.73 | 75.5% | 13 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.18 | 24.4% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $188.91 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $119.70 | 10 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $23.03 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| DOVATO dovato |
2025 | Dovato | 2024 | 143 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 29 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
143 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 505 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 321 | 58 |
| Gabapentin | Gabapentin | 224 | 44 |
| Montelukast Sodium | Montelukast Sodium | 204 | 43 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 203 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 37 |
| Potassium Chloride | Potassium Chloride | 178 | 36 |
| Tivicay | Dolutegravir Sodium | 167 | 20 |
| Furosemide | Furosemide | 159 | 42 |
| Dovato | Dolutegravir Sodium/Lamivudine | 143 | 13 |
| Losartan Potassium | Losartan Potassium | 141 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 140 | 30 |
| Omeprazole | Omeprazole | 129 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 22 |
| Metformin Hcl | Metformin Hcl | 123 | 32 |
| Jardiance | Empagliflozin | 119 | 29 |
| Linzess | Linaclotide | 107 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 105 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 103 | 20 |
| Carvedilol | Carvedilol | 101 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 97 | 13 |
| Descovy | Emtricitabine/Tenofov Alafenam | 88 | suppressed |
| Glipizide | Glipizide | 80 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 79 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 77 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 73 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 25 |
| Ritonavir | Ritonavir | 63 | suppressed |
| Lisinopril | Lisinopril | 58 | 12 |
| Trazodone Hcl | Trazodone Hcl | 57 | 14 |
| Ezetimibe | Ezetimibe | 55 | 12 |
| Meloxicam | Meloxicam | 54 | 14 |
| Gemfibrozil | Gemfibrozil | 53 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | suppressed |
| Colchicine | Colchicine | 51 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 11 |
| Chlorthalidone | Chlorthalidone | 49 | 11 |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Allopurinol | Allopurinol | 48 | 14 |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 13 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 38 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Abacavir | Abacavir Sulfate | 37 | suppressed |
| Eliquis | Apixaban | 37 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 37 | suppressed |
| Simvastatin | Simvastatin | 36 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 35 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Prezista | Darunavir | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Darunavir | Darunavir | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Edurant | Rilpivirine Hcl | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 12 |
| Atenolol | Atenolol | 23 | suppressed |
| Azithromycin | Azithromycin | 23 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Isentress Hd | Raltegravir Potassium | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Isentress | Raltegravir Potassium | 15 | suppressed |
| Lamivudine | Lamivudine | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Maraviroc | Maraviroc | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Nevirapine | Nevirapine | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Dapsone | Dapsone | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Trogarzo | Ibalizumab-Uiyk | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Lamivudine Hbv | Lamivudine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $188.91 · 16 records | ViiV Healthcare Company | CABENUVA, DOVATO | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Dovato play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error